Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the latest acquisition ...

A team at Kobe University has created a game-changing resource for autism research: 63 mouse embryonic stem cell lines, each ...

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Crispr Therapeutics AG leverages CASGEVY's rollout, a robust pipeline in cardiovascular, oncology, & partnerships to large ...

Japanese researchers have successfully eliminated the extra chromosome responsible for Down syndrome using CRISPR gene ...

Amid a challenging gene editing climate, partnerships between researchers, regulators, and industry remain crucial for ...

For decades, researchers have wondered why some people with risky gene variants go on to develop Parkinson’s disease, while ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require an ...

The promise of genome editing to help understand human diseases and create new therapies is vast, but technological ...

Editas Medicine ( EDIT 12.04%) is a promising clinical-stage company that has captured Wall Street's attention at the ...